How much chemotherapy in advanced Hodgkin's disease? [2]

Annals of Oncology

Volumn 8, Issue 12, 1997, Pages 1281-1283

  Bjorkholm, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE SULFATE;

ADVANCED CANCER; CANCER INVASION; CANCER REGRESSION; HODGKIN DISEASE; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0031462392     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1008234413144     Document Type: Letter

References (4)

1. Longo D.L. Young R.C. Wesley M. Twenty years of MOPP therapy for Hodgkin's disease J Clin Oncol 4 1986 1295 1306
2. Björkholm M. Axdorph U. Grimfors G. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial Ann Oncol 6 1995 895 899
3. Somers R. Carde P. Henry-Amar M. A randomized study in stage IIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European organization for research and treatment of cancer lymphoma cooperative group and groupe Pierre-et-Marie-Curie controlled clinical trial J Clin Oncol 12 1994 279 287
4. Pavlovsky S. Schvartzman E. Lastin F. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease J Clin Oncol 15 1997 2652 2658